Effects of modified dose-dense Paclitaxel combined with Platinum neoadjuvant chemotherapy in treatment of patients with advanced ovarian cancer
Objective:To observe effects of modified dose-dense Paclitaxel combined with Platinum neoadjuvant chemotherapy in treatment of patients with advanced ovarian cancer.Methods:A prospective study was conducted on 112 patients with advanced ovarian cancer admitted to this hospital from March 2020 to March 2022.According to the random number table method,they were divided into control group and observation group,56 cases in each group.The control group was treated with traditional neoadjuvant chemotherapy regimen of Paclitaxel combined with Platinum,while the observation group was treated with modified dose-dense Paclitaxel combined with Platinum neoadjuvant chemotherapy.The disease control rate,the serum tumor markers[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),specific tissue polypeptide antigen(TPS)]levels,the incidence of adverse reactions,the metastasis rate,and the 6-month survival rate were compared between the two groups.Results:The disease control rate of the observation group was 80.36%(45/56),which was higher than the control group of 62.50%(35/56),and the difference was statistically significant(P<0.05).After the treatment,the levels of CA125,TPS and CEA in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of anemia,neutropenia/leukopenia and other adverse reactions between the two groups(P>0.05).The incidence of gastrointestinal adverse reactions in the observation group was 25.00%(14/56),which was lower than 44.64%(25/56)in the control group,and the difference was statistically significant(P<0.05).The metastasis rate of the observation group were lower than those of the control group,the 6-month survival rate was higher than that of the control group,and the differences were statistically significant(P<0.05).Conclusions:The modified dose-dense Paclitaxel combined with Platinum neoadjuvant chemotherapy in the treatment of the patients with advanced ovarian cancer can improve the disease control rate and the 6-month survival rate,and reduce the levels of serum tumor markers,the incidence of gastrointestinal adverse reactions,the tumor metastasis rate.Moreover,it is superior to the traditional neoadjuvant chemotherapy regimen of Paclitaxel combined with Platinum.
NETL
NSTL
万方数据
